Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy.
Source check: Source checked. Not independent scientific confirmation.
Finding: The checked primary abstract reports this specific result: Unverified Haiku assessment. Retrospective two-hospital cohort of HCC with portal vein invasion treated with TACE; ANN and prognostic model validated on an independent cohort. The abstract identifies the model or learned operation and an observed evaluation; the conclusion is limited to the reported study setting. Original PMC full-text Methods and Results were checked; date 2020-08-16 reconciled to the primary record.
Technology: Publisher/PMC Methods establish the learned model and its operation in the specific study.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Publisher/PMC Methods establish the learned model and its operation in the specific study.
- Test and result
- Publisher/PMC Results report the represented result and its cohort-specific scope.
- Limitation / still unknown
- Validation design and reported performance/comparison were checked in the full text and are stated narrowly.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8562278/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.